[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dystonias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dystonias":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100585181","attention-and-eye-movement-in-parkinsons-disease-100585181",false,"NCT06899022","Attention and Eye Movement in Parkinson's Disease","Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease","Inclusion Criteria\n\n* All Participants (Aim 1):\n\n  * Ability and willingness to provide signed informed consent for this study\n  * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider\n  * Age 19 - 90 years\n* DBS Participants (Aim 1):\n\n  * Diagnosis of idiopathic Parkinson's disease (PD), essential tremor (ET) or dystonia (DT).\n  * Scheduled for new implantation of a therapeutic DBS device targeted to subthalamic nucleus (STN), ventral intermediate nucleus of thalamus (VIM) or internal globus pallidus (GPi)\n* Comparison Participants (Aim 1):\n\n  o Selection by age matching to participants in PD group\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):\n\n  * Ability and willingness to provide signed informed consent for this study\n  * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider\n  * Age 19 - 90 years\n  * Scheduled for awake DBS implantation with clinical micro-electrode recordings (MER)\n  * Willing and able to engage in tasks during an awake surgical procedure\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):\n\n  * Ability and willingness to provide signed informed consent for this study\n  * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider\n  * Age 19 - 90 years\n  * Willing to undergo acute manipulations of DBS\n  * Able to tolerate acute changes of DBS\n\nExclusion Criteria\n\n* All Participants (Aim 1):\n\n  * Corrected visual acuity insufficient to perceptually judge face stimuli\n  * Inability to understand task instructions or complete task requirements\n* DBS Participants (Aim 1):\n\n  o Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control a slider\n* Healthy Comparison Participants (Aim 1):\n\n  o History of neurodegenerative disorder\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):\n\n  * Corrected visual acuity insufficient to perceptually judge face stimuli\n  * Inability to understand task instructions or complete task requirements\n  * Not undergoing awake DBS implantation\n  * Uncorrected visual acuity insufficient to perceptually judge face stimuli\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):\n\n  * Corrected visual acuity insufficient to perceptually judge face stimuli\n  * Inability to understand task instructions or complete task requirements\n  * Failure of DBS to achieve a therapeutic effect on motor symptoms",true,"ALL","19 Years","90 Years",{"count":21,"type":22},138,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognition in participants with Parkinson's disease (PD) and non-PD movement disorders, including essential tremor (ET) and dystonia (DT). The main questions it aims to answer are:\n\n* Does impaired control of attention and eye movement in PD alter how social cues are perceived and interpreted?\n* Does therapeutic DBS improve or worsen attentional and perceptual deficits for social cues in PD, ET and DT?\n* Can DBS be optimized to restore normal attentional control in PD while remaining an effective therapy for other aspects of the disorder.\n* What do parts of the brain targeted by DBS contribute to the control of attention?\n\nUsing an eye tracking camera, investigators will study how participants with PD, ET and DT look at and perceive facial expressions of emotion before and after starting DBS therapy, in comparison to a group of healthy participants without ET, PD, DT or DBS. Participants with PD, ET and DT will see and rate morphed facial expressions on a computer screen in three conditions:\n\n* Before starting DBS therapy (over approximately 1 hour).\n* In the operating room, during the standard procedure to implant DBS electrodes, while the participant is awake (for no more than 15 minutes).\n* After starting DBS therapy, with brief experimental changes of DBS stimulation level and frequency (over approximately 1 hour).",[28,29,30],"Essential Tremor","Parkinson's Disease (PD)","Dystonias",[32,33,34,35],"Deep Brain Stimulation","Attention","Perception","Eye movement","RECRUITING","2026-04-30",{"date":39,"type":40},"2026-05-05","ACTUAL",{"date":42,"type":40},"2025-09-22",{"date":44,"type":22},"2028-08",{"name":46,"class":47},"University of Nebraska","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":85,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100571728","neurosurgical-outcome-network-100571728","NCT06724029","Neurosurgical Outcome Network","Neurosurgical Outcome Network Per la Predizione Dell'Outcome in Neurochirurgia","NEON","Inclusion Criteria:\n\n* Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region)\n* Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial\u002Fparasellar development.\n* Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas)\n* Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute\u002Fsubacute\u002Fchronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery.\n* Spinal pathology: degenerative cervical (anterior\u002Fposterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology.\n* Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain\u002Falgia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus.\n* Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section)\n* Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus.\n* For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology\n\nExclusion Criteria:\n\n* For cognitive and psychological assessment: patients with psychiatric diseases in history and\u002For taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.","18 Years",{"count":59,"type":22},4500,"OBSERVATIONAL","The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a \"common language\" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.",[63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,30,79,80,81,82,83,84],"Aneurysms","Arteriovenous Malformations","Cavernomas","Skull Base Tumors","Moyamoya Disease","Dural Fistulas","Subdural Hematoma","Extradural Hematoma","Subarachnoid Hemorrhage","Hydrocephalus","Parkinson&Amp;#39;s Disease","Spasticity","Trigeminal Neuralgia","Craniofacial Pain","Neuropathic Pain","Tremor","Obsessive-compulsive Disorder","Drug-resistant Epilepsy","Depression","Normal Pressure Hydrocephalus","Tumors of Peripheral Nerves","Chiari Malformation Type 1",[86],"Neurosurgery Outcome Artificial Intelligence predictors","2026-03-25",{"date":89,"type":40},"2026-03-30",{"date":91,"type":40},"2022-12-05",{"date":93,"type":22},"2027-06",{"name":95,"class":47},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",27]